FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386623560> ?p ?o ?g. }

• W4386623560 abstract "Ceftolozane/tazobactam is approved for the treatment of patients from birth to <18 y old with complicated urinary tract infections (cUTI). This post hoc analysis evaluated the safety, efficacy, and pharmacokinetics (PK) of ceftolozane/tazobactam compared with meropenem in neonates and young infants. NCT03230838 was a phase 2, randomized, active comparator-controlled, double-blind study of patients from birth to <18 y of age with cUTI, including pyelonephritis, given ceftolozane/tazobactam or meropenem in a 3:1 ratio. This subset analysis included only neonates and young infants < 3 mo of age. The microbiologic modified intent-to-treat population (mMITT) included 20 patients (ceftolozane/tazobactam, n = 14; meropenem, n = 6). All patients had pyelonephritis at baseline; two patients in each treatment group had bacteremia (overall 4/20, 20%). Escherichia coli was the most common baseline pathogen (overall 16/20, 80%). Safety and efficacy results were similar between treatment groups and consistent with the overall pediatric population. There were no serious drug-related adverse events (AEs), no discontinuations due to AEs, and no AEs leading to death in either treatment group. For the ceftolozane/tazobactam and meropenem treatment groups, clinical cure rates in the mMITT population were 92.9% and 100%, respectively. The population PK analysis of neonates and young infants demonstrated similar ceftolozane and tazobactam exposures to those of adults, achieving pharmacodynamic targets associated with clinical and microbiologic cure. Ceftolozane/tazobactam has a favorable safety profile and achieves high clinical cure and microbiologic eradication rates in neonates and young infants < 3 mo of age with cUTI and pyelonephritis. IMPORTANCE Extrapolation of antibacterial agent pharmacokinetics from adults to newborns and young infants may not be appropriate; similarly, the clinical manifestations of infectious diseases and outcomes following antibacterial treatment may not be similar. Ceftolozane/tazobactam is an antibacterial drug combination active against Pseudomonas aeruginosa and other multidrug-resistant gram-negative bacteria. A clinical study led to the approval for ceftolozane/tazobactam in patients from birth to 18 y of age who have complicated urinary tract infections, including those with serious kidney infections. Based on data collected during that clinical study, we compared newborns and young infants who were treated with ceftolozane/tazobactam (14 patients) and those who were treated with meropenem (6 patients). We found that ceftolozane/tazobactam treatment of newborns and young infants up to 3 mo of age who have complicated urinary tract infections demonstrated a favorable safety profile and high clinical cure and microbiologic eradication rates, similar to meropenem." @default.
• W4386623560 created "2023-09-13" @default.
• W4386623560 creator A5000568465 @default.
• W4386623560 creator A5009027708 @default.
• W4386623560 creator A5014459078 @default.
• W4386623560 creator A5019743351 @default.
• W4386623560 creator A5019823948 @default.
• W4386623560 creator A5039271207 @default.
• W4386623560 creator A5074390986 @default.
• W4386623560 creator A5079749370 @default.
• W4386623560 date "2023-09-12" @default.
• W4386623560 modified "2023-09-26" @default.
• W4386623560 title "Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis" @default.
• W4386623560 cites W1568287799 @default.
• W4386623560 cites W1970540449 @default.
• W4386623560 cites W1990935717 @default.
• W4386623560 cites W2003224687 @default.
• W4386623560 cites W2033829367 @default.
• W4386623560 cites W2072626952 @default.
• W4386623560 cites W2084510697 @default.
• W4386623560 cites W2117930563 @default.
• W4386623560 cites W2122855609 @default.
• W4386623560 cites W2150698282 @default.
• W4386623560 cites W2339454548 @default.
• W4386623560 cites W2344389263 @default.
• W4386623560 cites W2410982809 @default.
• W4386623560 cites W2501772594 @default.
• W4386623560 cites W2530533043 @default.
• W4386623560 cites W2554695371 @default.
• W4386623560 cites W2621089878 @default.
• W4386623560 cites W2765443258 @default.
• W4386623560 cites W2889158930 @default.
• W4386623560 cites W2936169514 @default.
• W4386623560 cites W3000059310 @default.
• W4386623560 cites W3087056791 @default.
• W4386623560 cites W3177629744 @default.
• W4386623560 cites W3196438426 @default.
• W4386623560 cites W4200326552 @default.
• W4386623560 cites W4316080643 @default.
• W4386623560 cites W4317776057 @default.
• W4386623560 doi "https://doi.org/10.1128/spectrum.01800-23" @default.
• W4386623560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37698430" @default.
• W4386623560 hasPublicationYear "2023" @default.
• W4386623560 type Work @default.
• W4386623560 citedByCount "0" @default.
• W4386623560 crossrefType "journal-article" @default.
• W4386623560 hasAuthorship W4386623560A5000568465 @default.
• W4386623560 hasAuthorship W4386623560A5009027708 @default.
• W4386623560 hasAuthorship W4386623560A5014459078 @default.
• W4386623560 hasAuthorship W4386623560A5019743351 @default.
• W4386623560 hasAuthorship W4386623560A5019823948 @default.
• W4386623560 hasAuthorship W4386623560A5039271207 @default.
• W4386623560 hasAuthorship W4386623560A5074390986 @default.
• W4386623560 hasAuthorship W4386623560A5079749370 @default.
• W4386623560 hasBestOaLocation W43866235601 @default.
• W4386623560 hasConcept C126322002 @default.
• W4386623560 hasConcept C187212893 @default.
• W4386623560 hasConcept C197934379 @default.
• W4386623560 hasConcept C2776685102 @default.
• W4386623560 hasConcept C2778266534 @default.
• W4386623560 hasConcept C2779375183 @default.
• W4386623560 hasConcept C2779443120 @default.
• W4386623560 hasConcept C2779631663 @default.
• W4386623560 hasConcept C2908647359 @default.
• W4386623560 hasConcept C501593827 @default.
• W4386623560 hasConcept C71924100 @default.
• W4386623560 hasConcept C86803240 @default.
• W4386623560 hasConcept C89423630 @default.
• W4386623560 hasConcept C94665300 @default.
• W4386623560 hasConcept C99454951 @default.
• W4386623560 hasConceptScore W4386623560C126322002 @default.
• W4386623560 hasConceptScore W4386623560C187212893 @default.
• W4386623560 hasConceptScore W4386623560C197934379 @default.
• W4386623560 hasConceptScore W4386623560C2776685102 @default.
• W4386623560 hasConceptScore W4386623560C2778266534 @default.
• W4386623560 hasConceptScore W4386623560C2779375183 @default.
• W4386623560 hasConceptScore W4386623560C2779443120 @default.
• W4386623560 hasConceptScore W4386623560C2779631663 @default.
• W4386623560 hasConceptScore W4386623560C2908647359 @default.
• W4386623560 hasConceptScore W4386623560C501593827 @default.
• W4386623560 hasConceptScore W4386623560C71924100 @default.
• W4386623560 hasConceptScore W4386623560C86803240 @default.
• W4386623560 hasConceptScore W4386623560C89423630 @default.
• W4386623560 hasConceptScore W4386623560C94665300 @default.
• W4386623560 hasConceptScore W4386623560C99454951 @default.
• W4386623560 hasLocation W43866235601 @default.
• W4386623560 hasLocation W43866235602 @default.
• W4386623560 hasOpenAccess W4386623560 @default.
• W4386623560 hasPrimaryLocation W43866235601 @default.
• W4386623560 hasRelatedWork W1999081204 @default.
• W4386623560 hasRelatedWork W2473381190 @default.
• W4386623560 hasRelatedWork W2786931538 @default.
• W4386623560 hasRelatedWork W2897404290 @default.
• W4386623560 hasRelatedWork W2981961248 @default.
• W4386623560 hasRelatedWork W3005833369 @default.
• W4386623560 hasRelatedWork W3040802235 @default.
• W4386623560 hasRelatedWork W4225996540 @default.
• W4386623560 hasRelatedWork W4386501739 @default.
• W4386623560 hasRelatedWork W828686235 @default.
• W4386623560 isParatext "false" @default.

• next